Logo image of LENZ

LENZ THERAPEUTICS INC (LENZ) Stock Fundamental Analysis

NASDAQ:LENZ - US52635N1037 - Common Stock

38.2 USD
+0.83 (+2.22%)
Last: 8/28/2025, 7:25:55 PM
37.98 USD
-0.22 (-0.58%)
After Hours: 8/28/2025, 7:25:55 PM
Fundamental Rating

3

Overall LENZ gets a fundamental rating of 3 out of 10. We evaluated LENZ against 193 industry peers in the Pharmaceuticals industry. While LENZ has a great health rating, there are worries on its profitability. LENZ is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LENZ has reported negative net income.
LENZ had a negative operating cash flow in the past year.
In the past 5 years LENZ always reported negative net income.
LENZ had a negative operating cash flow in each of the past 5 years.
LENZ Yearly Net Income VS EBIT VS OCF VS FCFLENZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

LENZ has a Return On Assets (-24.11%) which is comparable to the rest of the industry.
The Return On Equity of LENZ (-25.39%) is better than 64.25% of its industry peers.
Industry RankSector Rank
ROA -24.11%
ROE -25.39%
ROIC N/A
ROA(3y)-40.22%
ROA(5y)-88.15%
ROE(3y)-42.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LENZ Yearly ROA, ROE, ROICLENZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LENZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LENZ Yearly Profit, Operating, Gross MarginsLENZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, LENZ has more shares outstanding
LENZ has less shares outstanding than it did 5 years ago.
There is no outstanding debt for LENZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LENZ Yearly Shares OutstandingLENZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
LENZ Yearly Total Debt VS Total AssetsLENZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

LENZ has an Altman-Z score of 57.39. This indicates that LENZ is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of LENZ (57.39) is better than 98.45% of its industry peers.
There is no outstanding debt for LENZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 57.39
ROIC/WACCN/A
WACCN/A
LENZ Yearly LT Debt VS Equity VS FCFLENZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 20.54 indicates that LENZ has no problem at all paying its short term obligations.
With an excellent Current ratio value of 20.54, LENZ belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
A Quick Ratio of 20.54 indicates that LENZ has no problem at all paying its short term obligations.
LENZ has a better Quick ratio (20.54) than 90.67% of its industry peers.
Industry RankSector Rank
Current Ratio 20.54
Quick Ratio 20.54
LENZ Yearly Current Assets VS Current LiabilitesLENZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.13% over the past year.
EPS 1Y (TTM)80.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.44% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.69%
EPS Next 2Y20.38%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LENZ Yearly Revenue VS EstimatesLENZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 20M 40M 60M 80M 100M
LENZ Yearly EPS VS EstimatesLENZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LENZ. In the last year negative earnings were reported.
Also next year LENZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LENZ Price Earnings VS Forward Price EarningsLENZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LENZ Per share dataLENZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

LENZ's earnings are expected to grow with 23.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.38%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

LENZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LENZ THERAPEUTICS INC

NASDAQ:LENZ (8/28/2025, 7:25:55 PM)

After market: 37.98 -0.22 (-0.58%)

38.2

+0.83 (+2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners100.07%
Inst Owner Change15.53%
Ins Owners2.76%
Ins Owner Change-42.09%
Market Cap1.09B
Analysts87.14
Price Target50.71 (32.75%)
Short Float %13.96%
Short Ratio7.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.07%
Min EPS beat(2)6.09%
Max EPS beat(2)18.05%
EPS beat(4)3
Avg EPS beat(4)8.72%
Min EPS beat(4)-9.11%
Max EPS beat(4)19.83%
EPS beat(8)4
Avg EPS beat(8)-64.09%
EPS beat(12)6
Avg EPS beat(12)-61.1%
EPS beat(16)8
Avg EPS beat(16)-47.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.62%
PT rev (3m)12.62%
EPS NQ rev (1m)4.81%
EPS NQ rev (3m)1.08%
EPS NY rev (1m)7.64%
EPS NY rev (3m)8.04%
Revenue NQ rev (1m)104.85%
Revenue NQ rev (3m)36.57%
Revenue NY rev (1m)81.95%
Revenue NY rev (3m)80.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 217.89
P/FCF N/A
P/OCF N/A
P/B 5.28
P/tB 5.28
EV/EBITDA N/A
EPS(TTM)-1.88
EYN/A
EPS(NY)-2.63
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0.18
BVpS7.24
TBVpS7.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.11%
ROE -25.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.22%
ROA(5y)-88.15%
ROE(3y)-42.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 761.11%
Cap/Sales 13.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.54
Quick Ratio 20.54
Altman-Z 57.39
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)512.78%
Cap/Depr(5y)723.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.5%
EPS Next Y43.69%
EPS Next 2Y20.38%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.01%
EBIT Next 3Y26.66%
EBIT Next 5YN/A
FCF growth 1Y45.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.52%
OCF growth 3YN/A
OCF growth 5YN/A